The market has treated Daito Pharmaceutical like a slow burn value story, yet the latest quarter lands with more of a quiet reset than a clean win. The stock comes into this print at ¥1,383 after steady gains in recent months, while the new Q1 2027 figures show revenue of ¥11,894m and net income of ¥700m that sit below the recent high watermark. The real headline is margin and profit pressure. Earnings per share of ¥24.63 JPY trails the last couple of quarters, which puts the recent enthusiasm in the share price under a harsher light.
Like the steady share price climb but uneasy about Daito Pharmaceutical's softer profits this quarter and the pressure on earnings per share? Benchmark this update against 22 resilient stocks with low risk scores for companies where balance sheets and risk profiles look more resilient.
Q1 2027 Earnings Summary
- Revenue (Q1 2027 vs. Q1 2026): ¥11,894m vs. ¥13,011m (lower quarterly top line year on year)
- Net Income (Q1 2027 vs. Q1 2026): ¥700m vs. ¥696m (broadly flat quarterly profit level)
- Basic EPS (Q1 2027 vs. Q1 2026): ¥24.63 vs. ¥23.21 (modest earnings per share improvement)
- Trailing Net Profit Margin (Last 12 Months vs. Prior Year): 6.4% vs. 3.9% (profitability ratio higher than a year ago)
Prefer clean visuals over slogging through another wall of figures and footnotes? View a full picture of Daito Pharmaceutical with easy charts that highlight its valuation profile in the company report for Daito Pharmaceutical.
Daito Pharmaceutical: Bull Case Meets Mixed Earnings
The long-running idea around Daito Pharmaceutical is a diversified pharma supplier that can feel relatively steady. Recent figures partly fit that story. Net income in Q1 2027 is similar to Q1 2026 and basic EPS edges higher, which lines up with a resilience narrative. A higher trailing net profit margin of 6.4% versus 3.9% a year earlier also points to firmer profitability over the last year. The newly announced buyback plan adds another shareholder friendly signal, suggesting management sees enough balance sheet strength to retire shares.
Profit Pressure Keeps Bearish Concerns Alive
The bear side focuses on pressure in a competitive generics and contract manufacturing space. Revenue in Q1 2027 is lower than the same quarter last year, so top line momentum looks softer. Earnings per share in the latest quarter trails recent peaks, which sits awkwardly next to the stock’s recent climb. That tension between a firm margin over the last 12 months and weaker quarterly sales gives cautious investors room to question how robust the underlying demand and pricing power really are.
Access the analyst estimates for Daito Pharmaceutical to see where the consensus models start to diverge on Daito Pharmaceutical's next fiscal year and whether this seemingly quiet share price masks a sharper multi year inflection point in revenue and earnings expectations.
Stay Ahead Of Your Next Move
If Daito Pharmaceutical's mix of firmer trailing margins and softer recent revenue has your attention, register for free with Simply Wall St and add it to a Watchlist so you can track price against fair value and wait for your preferred entry point. After you have taken a position, keep your holdings organised in the Portfolio Command Center so you only see focused alerts on material events that really matter to your thesis. For longer term decisions, lean on the Community to see how other investors are thinking about the same risks and opportunities. By surfacing potential catalysts and warning signs early, Simply Wall St helps you move faster and stay ahead of the market.
Seeking Fresh Alternatives Beyond Daito Pharmaceutical
Markets move fast and the most interesting ideas do not stay quiet for long. Spot breakout potential and fresh momentum while it still matters. Get in early.
- Scan for resilient cash generators before they get fully priced, using the curated list of solid balance sheet and fundamentals stocks (21 results) that highlights businesses with balance sheets built to handle rougher market patches.
- Hunt for consistent income streams while yields still look appealing by tapping into the hand picked 31 dividend fortresses that focuses on companies prioritising reliable cash returns.
- Track potential market leaders riding the AI build out by reviewing the carefully filtered 92 AI infrastructure stocks where real revenue and mission critical technology already intersect.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com